NCT06293417 To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
| NCT ID | NCT06293417 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Korea University Anam Hospital |
| Condition | T2DM (Type 2 Diabetes Mellitus) |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,958 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,958 participants in total. It began in 2024-03-01 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this Randomized controlled trials is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: * major adverse cardiovascular events within 48 months of the trial duration * microvascular events within 48 months of the trial duration
Eligibility Criteria
Inclusion Criteria: * Patients with type 2 diabetes diagnosed by American Diabetes Association criteria * Age ≥ 19 years * Non-HDL-C ≥100 mg/dL, TG ≥200, \<500 mg/dL on moderate-intensity statins * with cardiovascular risk factor Exclusion Criteria: * Pregnant or breastfeeding women * Uncontrolled hyperglycemia(more than 12.0% for Subject treated with anti-diabetic treatment.) * Patient with myopathy and rhabdomyolysis * AST/ALT more than 3 ULN * Clinical evidence of genetic disorders such as galactose intolerance, Lapp lactose deficiency, and/or glucose-galactose malabsorption
Contact & Investigator
SIN-GON KIM
PRINCIPAL INVESTIGATOR
Korea University Anam Hospital
Frequently Asked Questions
Who can join the NCT06293417 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying T2DM (Type 2 Diabetes Mellitus). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06293417 currently recruiting?
Yes, NCT06293417 is actively recruiting participants. Contact the research team at k50367@korea.ac.kr for enrollment information.
Where is the NCT06293417 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06293417 clinical trial?
NCT06293417 is sponsored by Korea University Anam Hospital. The principal investigator is SIN-GON KIM at Korea University Anam Hospital. The trial plans to enroll 3,958 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.